

Figure S3. CD-HIT clustering of paired HC CDR3 and LC CDR3 sequences across four IPAH patients. The HC and LC CDR3 amino acid sequences from each single cell were concatenated together, separated by a 5 amino acid spacer sequence. Sequences were clustered using the CD-HIT algorithm, with a cutoff of 0.8 (including the spacer). Networks were visualized using the igraph package for R, with only multi-sequence clusters displayed on the graph.




Figure S4. Peripheral blood plasmablast gating hierarchy. Freshly isolated PBMCs from IPAH subjects and healthy controls were stained with fluorescently labeled antibodies in Hank's Balanced Salt Solution (HBSS) with 2% fetal bovine serum prior to flow cytometric analysis. Plasmablasts were defined as CD19⁺CD3⁻CD14⁻IgD⁻CD20^{lo/-}CD27⁺CD38^{hi} live single cells. To convey population hierarchy, labels above each plot indicate prior gating of the population shown and labels below each plot indicate the name of the gate shown in the plot above. Percent labels indicate the percent of the population shown that fall within each gate.




Figure S5. HUVEC stimulation gating hierarchy. HUVECs were harvested during the third to fifth passage and stimulated *in vitro* with (A) control or (B) PAH-derived recombinant mAbs prior to staining in Hank's Balanced Salt Solution with 2% fetal bovine serum. To convey population hierarchy, labels above each plot indicate prior gating of the population shown and labels below each plot indicate the name of the gate shown in the plot above. Percent labels indicate the percent of the population shown that fall within each gate.

Table S1. Univariate relationship between %IgA Plasmablasts and PAH risk markers.

PAH risk marker	Spearman correlation	p-value*
Age	0.086	0.679
NYHA functional class	0.012	0.952
Six-minute walk distance	-0.014	0.95
NT-proBNP	0.115	0.583
Glomerular filtration rate	0.055	0.793
DLCO	0.228	0.318
Mean pulmonary arterial pressure	0.049	0.822
Right atrial pressure	0.357	0.095
Pulmonary vascular resistance	-0.162	0.461
Cardiac index	0.041	0.853

* Spearman's correlation test

Table S2. Univariate relationship between %IgA Plasmablasts and Sex, Race, and comorbid conditions.

	% IgA Plasmablasts median (IQR)	p-value†
<i>Sex</i>		
Male	51.5 (17.0)	0.52
Female	46.1 (27.4)	
<i>Race</i>		
White	39.6 (31.2)	0.18
Non-white	52.1 (15.4)	
<i>Essential hypertension</i>		
Yes	60.3 (37.1)	0.18
No	46.2 (18.3)	
<i>Renal dysfunction (GFR < 60)</i>		
Yes	26.2 (35.0)	0.19
No	50.9 (10.8)	
<i>Diabetes history</i>		
Yes	41.4 (45.1)	0.72
No	46.3 (14.5)	
<i>Asthma history</i>		
Yes	41.8 (53.1)	0.61
No	48.6 (17.2)	

† Wilcoxon rank sum test

Table S3. Clinical comparison of High vs. Low IgA plasmablast subgroups.

	High IgA PB (n=13)	Low IgA PB n=(12)	p-value[#]
<i>Female sex, n (%)</i>	9 (69.2%)	10 (83.3%)	0.64
<i>NYHA functional class, n (%)</i>			
Class I or II	7 (54%)	6 (50%)	0.99
Class III	5 (38.4%)	5 (41.7%)	0.99
Class IV	1 (7.7%)	1 (8.3%)	0.99
<i>Background PAH therapy, n (%)</i>			
Treatment naïve	4 (30.8%)	4 (33.3%)	0.99
Dual or triple therapy	4 (30.8%)	4 (33.3%)	0.99
Prostanoid therapy	5 (38.5%)	6 (50%)	0.69
<i>Age, years, median (IQR)</i>	53.1 (33.2)	62.6 (18.6)	0.51
<i>6MWD, m, median (IQR)</i>	465.5 (182.5)	388.5 (166.5)	0.22
<i>NT-proBNP, pg/mL, median (IQR)</i>	129 (244)	154 (785)	0.83
<i>DLCO, % predicted, median (IQR)</i>	75.0 (18.3)	61 (27.0)	0.14
<i>Estimated GFR, median (IQR)</i>	82.3 (28.1)	53.5 (25.9)	0.16
<i>RHC measurements, median (IQR)</i>			
mPAP, mmHg	40.0 (7.5)	40 (23.5)	0.85
RAP, mmHg	9.5 (6.5)	9 (5)	0.97
PVR, Wood units	7.4 (4.6)	8.1 (7.2)	0.46
Cardiac index, ml/min/m ²	2.2 (0.49)	2.0 (0.5)	0.58

Fisher's exact test for categorical variables (Sex, NYHA class, therapy); Kruskal-Wallis test for continuous variables.

Table S4. Oligonucleotide sequences used in the study

Name	Sequence	Step
wellID_002	CACGACCGGTGCTCGATTTAGTACACGTGATAGGG	RT
wellID_003	CACGACCGGTGCTCGATTTAGTACAGATCGTAGGG	RT
wellID_005	CACGACCGGTGCTCGATTTAGTAGTGTAGATAGGG	RT
wellID_006	CACGACCGGTGCTCGATTTAGTCGCACTAGTAGGG	RT
wellID_007	CACGACCGGTGCTCGATTTAGTCTAGCGACTAGGG	RT
wellID_008	CACGACCGGTGCTCGATTTAGTGTGAGTAGTAGGG	RT
wellID_010	CACGACCGGTGCTCGATTTAGACGCGATCGAAGGG	RT
wellID_013	CACGACCGGTGCTCGATTTAGAGTATACATAAGGG	RT
wellID_014	CACGACCGGTGCTCGATTTAGAGTCGAGAGAAGGG	RT
wellID_015	CACGACCGGTGCTCGATTTAGAGTGCTACGAAGGG	RT
wellID_017	CACGACCGGTGCTCGATTTAGCGCAGTACGAAGGG	RT
wellID_018	CACGACCGGTGCTCGATTTAGCGCGTATACAAGGG	RT
wellID_020	CACGACCGGTGCTCGATTTAGCGTACTCAGAAGGG	RT
wellID_021	CACGACCGGTGCTCGATTTAGCTACGCTCTAAGGG	RT
wellID_022	CACGACCGGTGCTCGATTTAGTACGTCATCAAGGG	RT
wellID_024	CACGACCGGTGCTCGATTTAGTCACGCGAGAAGGG	RT
wellID_025	CACGACCGGTGCTCGATTTAGTCGATAGTGAAGGG	RT
wellID_026	CACGACCGGTGCTCGATTTAGTCGCTGCGTAAGGG	RT
wellID_030	CACGACCGGTGCTCGATTTAGTGTGTCGCAAGGG	RT
wellID_035	CACGACCGGTGCTCGATTTAGACTCATCTACAGGG	RT
wellID_036	CACGACCGGTGCTCGATTTAGACTCGCGCACAGGG	RT
wellID_037	CACGACCGGTGCTCGATTTAGAGAGCGTCACAGGG	RT
wellID_039	CACGACCGGTGCTCGATTTAGAGTAGTGATCAGGG	RT
wellID_043	CACGACCGGTGCTCGATTTAGCACGTAGATCAGGG	RT
wellID_044	CACGACCGGTGCTCGATTTAGCACGTGTCGACAGGG	RT
wellID_046	CACGACCGGTGCTCGATTTAGCGACACTATCAGGG	RT
wellID_047	CACGACCGGTGCTCGATTTAGCGAGACGCGCAGGG	RT
wellID_048	CACGACCGGTGCTCGATTTAGCGTCGATCTCAGGG	RT
wellID_051	CACGACCGGTGCTCGATTTAGCTCTACGCTCAGGG	RT
wellID_055	CACGACCGGTGCTCGATTTAGTAGCTCTATCAGGG	RT
wellID_057	CACGACCGGTGCTCGATTTAGTCACTCATAACAGGG	RT
wellID_058	CACGACCGGTGCTCGATTTAGTCATCGAGTCAGGG	RT
wellID_059	CACGACCGGTGCTCGATTTAGTCGAGCTCTCAGGG	RT
wellID_062	CACGACCGGTGCTCGATTTAGTGCTATAGACAGGG	RT
wellID_069	CACGACCGGTGCTCGATTTAGATAGCTCTCGAGGG	RT
wellID_081	CACGACCGGTGCTCGATTTAGTAGCATACTGAGGG	RT
wellID_082	CACGACCGGTGCTCGATTTAGTATCTGATAGAGGG	RT
wellID_083	CACGACCGGTGCTCGATTTAGTCTGATCGAGAGGG	RT
wellID_089	CACGACCGGTGCTCGATTTAGTGTATCACAGAGGG	RT

wellID_092	CACGACCGGTGCTCGATTTAGAAGCAGGAAATGGG	RT
wellID_093	CACGACCGGTGCTCGATTTAGAAGTCTGCATTGGG	RT
wellID_094	CACGACCGGTGCTCGATTTAGAATCGGAGCGTGGG	RT
wellID_097	CACGACCGGTGCTCGATTTAGACACGACAACTGGG	RT
wellID_100	CACGACCGGTGCTCGATTTAGACAGTCTTCCTGGG	RT
wellID_101	CACGACCGGTGCTCGATTTAGACCCTTGGTGTGGG	RT
wellID_104	CACGACCGGTGCTCGATTTAGACTGCAACCGTGGG	RT
wellID_106	CACGACCGGTGCTCGATTTAGAGACACGTCTTGGG	RT
wellID_107	CACGACCGGTGCTCGATTTAGAGAGGGCGATTGGG	RT
wellID_108	CACGACCGGTGCTCGATTTAGAGCAGCAGTATGGG	RT
wellID_109	CACGACCGGTGCTCGATTTAGAGCCAATACTGGG	RT
wellID_111	CACGACCGGTGCTCGATTTAGAGCTCGCTCTTGGG	RT
wellID_112	CACGACCGGTGCTCGATTTAGAGGACTTGCCTGGG	RT
wellID_113	CACGACCGGTGCTCGATTTAGAGGTATCGTATGGG	RT
wellID_114	CACGACCGGTGCTCGATTTAGAGTGGATCACTGGG	RT
wellID_115	CACGACCGGTGCTCGATTTAGAGTTGTGCCATGGG	RT
wellID_118	CACGACCGGTGCTCGATTTAGATCCGCCTTGTGGG	RT
wellID_119	CACGACCGGTGCTCGATTTAGATCCTCAACATGGG	RT
wellID_122	CACGACCGGTGCTCGATTTAGCAATCCTGTTTGGG	RT
wellID_123	CACGACCGGTGCTCGATTTAGCAATTCGAGCTGGG	RT
wellID_126	CACGACCGGTGCTCGATTTAGCAGGCGAACTTGGG	RT
wellID_127	CACGACCGGTGCTCGATTTAGCAGTTTCTGTTGGG	RT
wellID_129	CACGACCGGTGCTCGATTTAGCCAATCAACTTGGG	RT
wellID_130	CACGACCGGTGCTCGATTTAGCCACGTGGAATGGG	RT
wellID_133	CACGACCGGTGCTCGATTTAGCCCATACTATTGGG	RT
wellID_135	CACGACCGGTGCTCGATTTAGCCGCTCGTTTTGGG	RT
wellID_136	CACGACCGGTGCTCGATTTAGCCGTTTATCTGGG	RT
wellID_143	CACGACCGGTGCTCGATTTAGCTACCGCTGTTGGG	RT
wellID_144	CACGACCGGTGCTCGATTTAGCTCACGGAAGTGGG	RT
wellID_145	CACGACCGGTGCTCGATTTAGCTCTTCGGATTGGG	RT
wellID_146	CACGACCGGTGCTCGATTTAGCTGCAAGCTGTGGG	RT
wellID_153	CACGACCGGTGCTCGATTTAGGAAGAACAGTTGGG	RT
wellID_158	CACGACCGGTGCTCGATTTAGGACGATATCCTGGG	RT
wellID_159	CACGACCGGTGCTCGATTTAGGAGCACACTTTGGG	RT
wellID_162	CACGACCGGTGCTCGATTTAGGCACTCTGGTTGGG	RT
wellID_163	CACGACCGGTGCTCGATTTAGGCACTTCCAGTGGG	RT
wellID_164	CACGACCGGTGCTCGATTTAGGCAGAGCTACTGGG	RT
wellID_167	CACGACCGGTGCTCGATTTAGGCGACGTTGTTGGG	RT
wellID_168	CACGACCGGTGCTCGATTTAGGCGTTCCTCATGGG	RT
wellID_169	CACGACCGGTGCTCGATTTAGGGACTATACATGGG	RT
wellID_171	CACGACCGGTGCTCGATTTAGGGCATTATTGTGGG	RT
wellID_172	CACGACCGGTGCTCGATTTAGGGCTCGACTATGGG	RT

wellID_174	CACGACCGGTGCTCGATTTAGGGGTGTTTATTGGG	RT
wellID_175	CACGACCGGTGCTCGATTTAGGGTACGGACATGGG	RT
wellID_176	CACGACCGGTGCTCGATTTAGGGTCAACGATTGGG	RT
wellID_177	CACGACCGGTGCTCGATTTAGGGTTCGGTGTATGGG	RT
wellID_178	CACGACCGGTGCTCGATTTAGGGTGTTACGTGGG	RT
wellID_180	CACGACCGGTGCTCGATTTAGGTTGTGGAGTTGGG	RT
wellID_183	CACGACCGGTGCTCGATTTAGTCAAACAGGATGGG	RT
wellID_184	CACGACCGGTGCTCGATTTAGTCAGGTCTCTTGGG	RT
wellID_185	CACGACCGGTGCTCGATTTAGTCATCCGCAGTGGG	RT
wellID_187	CACGACCGGTGCTCGATTTAGTCCTTTTGGATGGG	RT
wellID_191	CACGACCGGTGCTCGATTTAGTCTCGTTTACTGGG	RT
wellID_193	CACGACCGGTGCTCGATTTAGTGCAACTTCTGGG	RT
wellID_203	CACGACCGGTGCTCGATTTAGTTGGTTCGAGTGGG	RT
wellID_205	CACGACCGGTGCTCGATTTAGTTTACCTGGGTGGG	RT
wellID_207	CACGACCGGTGCTCGATTTAGTTTTGCAACGTGGG	RT
OligodTVN20	TTTTTTTTTTTTTTTTTTTTTVN	RT
PCR1_fwd	CACGACCGGTGCTCGATTTAG	PCR1
K_GSP1	TCTCCCCTGTTGAAGCTCTTTGTG	PCR1
L_GSP1	TYTGTGGGACTTCCACTGCTC	PCR1
G_GSP1	TCTTGTCCACCTTGGTGTGCTG	PCR1
A_GSP1	ATTCGTGTAGTGCTTCACGTG	PCR1
M_GSP1	CTCTCAGGACTGATGGGAAGC	PCR1
K_GSP2	TCCCTACACGACGCTCTTCCGATCTGAAGACAGATGGTGCAGCCACAG	PCR2
L_GSP2	TCCCTACACGACGCTCTTCCGATCTAGAGGAGGGYGGGAACAGAGTGA	PCR2
G_GSP2	TCCCTACACGACGCTCTTCCGATCTAAGACSGATGGGCCCTTGGTGA	PCR2
A_GSP2	TCCCTACACGACGCTCTTCCGATCTGAAGACCTGGGGCTGGTCG	PCR2
M_GSP2	TCCCTACACGACGCTCTTCCGATCTGAGACGAGGGGGAAAAGGGTT	PCR2
PCR2_Fwd	GACTGGAGTTCAGACGTGTGCTCTTCCGATCCACGACCGGTGCTCGATTTAG	PCR2
PCR3_Rev	AATGATACGGCGACCACCGAGATCTACACTCTTCCCTACACGACGCTCTT	PCR3
plateID_1	CAAGCAGAAGACGGCATAACGAGATCGTGATGTGACTGGAGTTCAGACGTG	PCR3
plateID_2	CAAGCAGAAGACGGCATAACGAGATACATCGGTGACTGGAGTTCAGACGTG	PCR3
plateID_3	CAAGCAGAAGACGGCATAACGAGATGCCTAAGTGACTGGAGTTCAGACGTG	PCR3
plateID_4	CAAGCAGAAGACGGCATAACGAGATTGGTCAGTGACTGGAGTTCAGACGTG	PCR3
plateID_5	CAAGCAGAAGACGGCATAACGAGATCACTGTGTGACTGGAGTTCAGACGTG	PCR3
plateID_6	CAAGCAGAAGACGGCATAACGAGATATTGGCGTGACTGGAGTTCAGACGTG	PCR3
plateID_7	CAAGCAGAAGACGGCATAACGAGATGATCTGGTGACTGGAGTTCAGACGTG	PCR3
plateID_8	CAAGCAGAAGACGGCATAACGAGATTCAAGTGTGACTGGAGTTCAGACGTG	PCR3
plateID_9	CAAGCAGAAGACGGCATAACGAGATCTGATCGTGACTGGAGTTCAGACGTG	PCR3
plateID_10	CAAGCAGAAGACGGCATAACGAGATAAGCTAGTGACTGGAGTTCAGACGTG	PCR3
plateID_11	CAAGCAGAAGACGGCATAACGAGATGTAGCCGTGACTGGAGTTCAGACGTG	PCR3
plateID_12	CAAGCAGAAGACGGCATAACGAGATTACAAGGTGACTGGAGTTCAGACGTG	PCR3
plateID_13	CAAGCAGAAGACGGCATAACGAGATTTGACTGTGACTGGAGTTCAGACGTG	PCR3

plateID_14	CAAGCAGAAGACGGCATAACGAGATGGAAGTGTGACTGGAGTTCAGACGTG	PCR3
plateID_15	CAAGCAGAAGACGGCATAACGAGATTGACATGTGACTGGAGTTCAGACGTG	PCR3
plateID_16	CAAGCAGAAGACGGCATAACGAGATGGACGGGTGACTGGAGTTCAGACGTG	PCR3
plateID_17	CAAGCAGAAGACGGCATAACGAGATCTCTACGTGACTGGAGTTCAGACGTG	PCR3
plateID_18	CAAGCAGAAGACGGCATAACGAGATGCGGACGTGACTGGAGTTCAGACGTG	PCR3
plateID_19	CAAGCAGAAGACGGCATAACGAGATTTTACGTGACTGGAGTTCAGACGTG	PCR3
plateID_20	CAAGCAGAAGACGGCATAACGAGATGGCCACGTGACTGGAGTTCAGACGTG	PCR3
plateID_21	CAAGCAGAAGACGGCATAACGAGATCGAAACGTGACTGGAGTTCAGACGTG	PCR3
plateID_22	CAAGCAGAAGACGGCATAACGAGATCGTACGGTACTGGAGTTCAGACGTG	PCR3
plateID_23	CAAGCAGAAGACGGCATAACGAGATCCACTCGTGACTGGAGTTCAGACGTG	PCR3
plateID_24	CAAGCAGAAGACGGCATAACGAGATGCTACCGTGACTGGAGTTCAGACGTG	PCR3
plateID_25	CAAGCAGAAGACGGCATAACGAGATATCAGTGTGACTGGAGTTCAGACGTG	PCR3
plateID_26	CAAGCAGAAGACGGCATAACGAGATGCTCATGTGACTGGAGTTCAGACGTG	PCR3
plateID_27	CAAGCAGAAGACGGCATAACGAGATAGGAATGTGACTGGAGTTCAGACGTG	PCR3
plateID_28	CAAGCAGAAGACGGCATAACGAGATCTTTGGTACTGGAGTTCAGACGTG	PCR3
plateID_29	CAAGCAGAAGACGGCATAACGAGATTAGTTGGTACTGGAGTTCAGACGTG	PCR3
plateID_30	CAAGCAGAAGACGGCATAACGAGATCCGGTGGTACTGGAGTTCAGACGTG	PCR3
plateID_31	CAAGCAGAAGACGGCATAACGAGATATCGTGGTACTGGAGTTCAGACGTG	PCR3
plateID_32	CAAGCAGAAGACGGCATAACGAGATTGAGTGGTACTGGAGTTCAGACGTG	PCR3
plateID_33	CAAGCAGAAGACGGCATAACGAGATCGCCTGGTACTGGAGTTCAGACGTG	PCR3
plateID_34	CAAGCAGAAGACGGCATAACGAGATGCCATGGTACTGGAGTTCAGACGTG	PCR3
plateID_35	CAAGCAGAAGACGGCATAACGAGATAAAATGGTACTGGAGTTCAGACGTG	PCR3
plateID_36	CAAGCAGAAGACGGCATAACGAGATTGTTGGGTACTGGAGTTCAGACGTG	PCR3
plateID_37	CAAGCAGAAGACGGCATAACGAGATATCCGGTACTGGAGTTCAGACGTG	PCR3
plateID_38	CAAGCAGAAGACGGCATAACGAGATAGCTAGGTACTGGAGTTCAGACGTG	PCR3
plateID_39	CAAGCAGAAGACGGCATAACGAGATGTATAGGTACTGGAGTTCAGACGTG	PCR3
plateID_40	CAAGCAGAAGACGGCATAACGAGATTCTGAGGTACTGGAGTTCAGACGTG	PCR3
plateID_41	CAAGCAGAAGACGGCATAACGAGATGTCGTCGTACTGGAGTTCAGACGTG	PCR3
plateID_42	CAAGCAGAAGACGGCATAACGAGATCGATTAGTGACTGGAGTTCAGACGTG	PCR3
plateID_43	CAAGCAGAAGACGGCATAACGAGATGCTGTAGTGACTGGAGTTCAGACGTG	PCR3
plateID_44	CAAGCAGAAGACGGCATAACGAGATATTATAGTGACTGGAGTTCAGACGTG	PCR3
plateID_45	CAAGCAGAAGACGGCATAACGAGATGAATGAGTGACTGGAGTTCAGACGTG	PCR3
plateID_46	CAAGCAGAAGACGGCATAACGAGATTCGGGAGTGACTGGAGTTCAGACGTG	PCR3
plateID_47	CAAGCAGAAGACGGCATAACGAGATCTTCGAGTGACTGGAGTTCAGACGTG	PCR3
plateID_48	CAAGCAGAAGACGGCATAACGAGATTGCCGAGTGACTGGAGTTCAGACGTG	PCR3

Table S5. Recombinant plasmablast antibody characteristics

mAB	Binding Hits	Origin Isotype	HC V Gene	LC V Gene	HC AA Sequence	LC AA Sequence
PAH1	Histone H2b, Histone H3	IgG	IGHV3-7	IGLV8-61	DVQLVESGGGLVHLGGSLRLSCAASGFTFSSVWMAWVRQAPGKGLWEWVANINPDGSDRYVDYVSKGRFTISRDNKATLSLQMNSLTVGDTGIYYCTRDLNWGADWGGTLTVTVSS	QTVVTQEPSPFSVSPGGTVTLTQGLSFGSVSPITYPSWYQQTPGQAPRALIYQNTNRSSGVPDRFSGSILGSKAALITGAQADDESYYCVLYMGGGWVFGGGTKLTVL
PAH4	FTCD (LC1)	IgG	IGHV1-8	IGKV1-5	QVQLVQSGTEVKKPGASVRVSCRASGYTFTNYDINWVRQAPGGQPEWWMGNPNSGNTGSPQNFRRVMTTRDSTSTAYMELSGLRSEDATVYYCARSPTRIGQWSPGIIRRFDLWGQGLVTVSS	DIQMTQSPSTLSASVGDRTVITCRASQSIRTLAWYQQKPKAPKLLIYEASTLESVPPNFSGSGSGETFTLTISLQPDFFATYYCQYQSTYSLTFGGGKVEIK
PAH5	Histone H1, U1-snRNP A	IgG	IGHV1-18	IGKV1-5	RVTLVQSGAELKRPASVKISCKASGYTFGNYGMINWVRQAPGLPEWLGWINCFDGKTFYAKQFQGRVAMTKDSTTTAYLDRSLRSDDTAIYYCARTLLGSDVLGTFDLWGQGTMTVTVSS	DIQMTQSPSTLSASVGDRTVITCRASQSIDSWLAWYQQNPKAPKLLIYKASRLGSEVPSRFSGSGSGETFTLTISLQPDFFATYYCQYQHYDYPWTFGGGKLEVK
PAH7	U-snRNP B/B' protein	IgG	IGHV3-30	IGKV1-12	QARLVQSGGGVHPGRRTLTLTCAASGFTFRTFGMHVWRQAPGRGLEWLVAVSHDGKTKYIDAVKRRFHIARDNSNSTLYLMDPPRESDATYFCAKDMWPESGSGYYFDQWGGQSVVIVSS	DVQMTQSPSFVSAVGDGVITTCRAGQNLNRLAWYQQKPKAPDLYLDVSTLQSGVPSRFSGSGSGRDFTLTISLQPEDSAIYFCQALVFKTLAWGPPQWRNSFGLGTTVEIK
PAH8	highly polyreactive	IgG	IGHV3-21	IGKV1-5	EVQLVESGGGLVKPGGSLRLSCAASGFSFSSYNMIWIRQAPGKGLWEVSSISSSSFIIYADSVKGRFSISRDNKDSVYLQMNLRRAEDATVYYCARDLKTWCSTNCSAWGRGLTVTVSS	DIQMTQSPSTLSASVGDRTVITCRANQINTLAWYQQKPKAPNLLVYRASLSELRGVPDRFSGSGSGETFTLTVSSLPDFFATYYCQYQISYPTWTFGGGKVEVR
PAH9	PCNA, Jo-1, PL-12, HUVECs, functional assay	IgA	IGHV1-18	IGKV1-27	QVQLVQSGAEVKKPGDSVRVSCRASGYTFNTYDINWVRQATGQGLEWWMGNPNSGNRNFQAKFRGRVTLTRDTSTDAYMELTGLTSEDSAVYYCTTERWDKWAQGYHYHGMVWVWGGGTTVTVSS	DIQMTQSPSSLASVGDSDVTITCRASQDISNLYAWYQQKPKVPLLIYGASTLQSGVPSRFSGSGSGETFTLTIGSLQPEDVATYYCQKYSTPRTFGGGKVEIK
PAH10	U1-snRNP A	IgA	IGHV3-53	IGLV1-47	EVQLVETGGGLMQPGSLRLSCATSGVTVSSNYMTWVRQAPGKGLWEVSVIYNGDRTYADSVRGRFTISRDNKKTLYLQMDNLRRAEDATVYYCARDPPGIAGPGQLYWGQGMPTVTVSS	QSVLTQPPSASGTPGQRVITSCSGSSNIATNYVYVYQQPFGTAPRLLIYINNRPSGVPDRFSAKSGTSASLAISGLRSEDEADYYCSAWDLRSGPVFVGGGKLAVAL
PAH11	PL-7, PCNA, Mi-2	IgA	IGHV3-23	IGKV3-15	EVQLLESGGGFLOPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLWEVSAISGR AATTYYADSVKGRFTISRDNKNTLYLQINSLRAEDTALYYCAKEESDVRNYYRHWFFDVWGRGLTVTVSS	EIVMTQSPVTLVSPGERVTLSCRASQSVRSNLAWYQQKPGQAPRLLIYGASTRATGIPSRISGSGSETDFTLTISLQSEDAIYYCQYNYWPMCSFGGGKLEIK
PAH15	Sp100, PCNA, PL-12, HUVECs	IgA	IGHV3-30-3	IGLV6-57	QVQMVSQGGVWQGRSLRLSCATSGFTFNRYAMHWVRQAPGKGLDWVAVISYDGSNKYYADFVKGRFSISRDNQNTLYLQMSLSLRPDDTAVYYCVDRSHAPLANPFAFNWRPWFPGWQGTIAVSS	NFMTLQPHSVSGSPGETVTMSCTRSSGAIGNNYVQVWHRQRPASPIIILYEDYERPPGVPDRFSGSIDSSNSASLTISGLKADEADYYCQSYSDSHSVVFGGGKTLTVL
PAH16	none	IgA	IGHV3-7	IGKV2-30	EVRLVESGGGLVQPGGSLRLSCAASGFSFRHYWMSWVRQAPGKGLWEWVANMNGGNERIYVDYVSKGRFTISRDNKATLSLFLQMNSLRVEDTAVYYCVGDDYGAHFDPRGRGLTVTVSS	EVVMTQSPVLPVTLGPASISCRSSQSLVSRDGNLYLHWFLQRPQQSPRRLIYKVSNRDSGVPDRFSGSGSGTDFLTISRVEAEDVGVYYCMQGSHPVPPWTFGGGKTVDIK
PAH17	none	IgG	IGHV3-30	IGKV1-12	QVRLQSGGGAVEPGRSVTLSCAGSGFTFGSYGMHWVRQAPGRGLEWLVAVSHDGSVKYIDVVKGRFTISRDNKNTLYFYMDAPRESDATYFCAKDIRAESGSGYYFDHWGQGSVIVSS	DVQMTQSPSSVSAFVRDRVITTCRASQNIIRLAWYQQKPKAPDLIYDASTLYSGVPSRFSGSGSGETFTLTISLQPEDSAVILSTGQRFPK NFWPGTKVEIK
PAH18	Fibromodulin peptide	IgA	IGHV1-8	IGKV1-5	QVQLVQSGAELRQPGASVKVSKASGYTFTSYDINWVRQAPGGQPEWWMGNPNSANTGFQNFGRVSLTRDVSISTAYMELSGLRFEDTAVYFCVRSPTIRIGKWSPIILRRFEFVWGGGALVTVSP	DIEMTQSPSTLSASVGERVITISCRASQYINTLAWYQQKPKAPKLLIYQASILETGVPPTFSGSGSGETFTLTISLQPDFFATYYCQYNTYSLTFGRGKVEVK
PAH19	Clusterin peptide, PL-12	IgG	IGHV3-23	IGLV2-14	QEQLVQSGAEVKKPGASVKVSKCTSGYTFTNYDINWVRQATGQGLEWWMGNPNSGNTNYAQKFGGRVIMTRDSTGTAYMELSSLSRSDDTAVYYCATEKWEKRGVY YYYGMDVWVWGGGTTVTVSS	DIQMTQSPSSLASVGDRTVITCRASQGINNLYAWYQQKPKVPLLIYASASTLQSGVPSRFSGSGSGETFTLTISLQPEDVATYYCQKYSTPRTFGGGKVEIK